Clinical trial · Interventional
The Effect of Octreotide on Wound Drainage After Mastectomy
The Effect of Octreotide on the Duration of Post-mastectomy Wound Drainage: a Randomized Controlled Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients who had mastectomy for breast cancer usually have drainage of some fluid from the site of surgery. This could be prolonged and may lead to other negative consequences after surgery. Octreotide could potentially reduce the amount of this drainage. In this study, patients were grouped into two: a first group that received octreotide injection and a second group that received a placebo. The study tested whether octreotide injection has any effect on the duration of fluid drainage from the surgery site after mastectomy for breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Seroma Following Procedure | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Octreotide Injection | Drug | — | UNRESOLVED |
| Sterile water | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Octreotide group
- description
- Received 100µg of octreotide intravenously 8-hourly for 5 days from the first post-operative day
- interventionNames
- Drug: Octreotide Injection
- type
- PLACEBO_COMPARATOR
- label
- Control group
- description
- Received 1ml of sterile water intravenously 8-hourly for 5 days from the first post-operative day
- interventionNames
- Other: Sterile water
Primary outcomes (1)
- measure
- Time to drain removal
- timeFrame
- 24 hours after surgery till a drain output of <40ml in the preceding 24hours
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * All female breast cancer patients requiring modified radical mastectomy Exclusion Criteria: * All mastectomies without axillary clearance (simple and toilet mastectomies) * Breast-conserving surgeries * Patients undergoing immediate breast reconstruction after mastectomy * Previous axillary surgery
References
Publications (4)
- BACKGROUNDMichalik T, Matkowski R, Biecek P, Szynglarewicz B. The use of ultrasonic scalpel lowers the risk of post-mastectomy seroma formation in obese women. J Cancer. 2019 Jun 9;10(15):3481-3485. doi: 10.7150/jca.29774. eCollection 2019. PMID 31293652
- BACKGROUNDvan Bemmel AJ, van de Velde CJ, Schmitz RF, Liefers GJ. Prevention of seroma formation after axillary dissection in breast cancer: a systematic review. Eur J Surg Oncol. 2011 Oct;37(10):829-35. doi: 10.1016/j.ejso.2011.04.012. Epub 2011 Aug 17. PMID 21849243
- BACKGROUNDCarcoforo P, Soliani G, Maestroni U, Donini A, Inderbitzin D, Hui TT, Lefor A, Avital I, Navarra G. Octreotide in the treatment of lymphorrhea after axillary node dissection: a prospective randomized controlled trial. J Am Coll Surg. 2003 Mar;196(3):365-9. doi: 10.1016/S1072-7515(02)01757-X. PMID 12648685
- BACKGROUNDOgundiran TO, Ayandipo OO, Ademola AF, Adebamowo CA. Mastectomy for management of breast cancer in Ibadan, Nigeria. BMC Surg. 2013 Dec 19;13:59. doi: 10.1186/1471-2482-13-59. PMID 24354443